Subsequent studies from other groups have confirmed our original findings.65 Pleiotropic effects involving distinctive receptors, including VEGFR2 and growth hormone receptors, distinctive pathways, including VEGFR2-AKT-eNOS, ERK , FAK-paxillin, FoxO3a, p-AKT, p-mTOR and p-GSK-3, and distinctive loops, including stimulation of the egr-1 gene and its corepressor gene naB2, and counteraction of increases in pro-inflammatory and procachectic cytokines, likely minimize the inherent lack of full understanding of the mechanisms that may be involved
These are adjuncts to diet and GLP-1 therapy, not primary weight-loss drugs.
A notable study showcased that participants receiving GLP-1 agonists reported a mean weight loss ranging between 3.0 and 3.6 kg over six months
Patient Benefits GLP-1 therapies provide multiple possible benefits for lipedema patients by addressing the metabolic and inflammatory processes that traditional diet and exercise are incapable of reversing
Most protocols range from 612 weeks, with reassessment every few months
Weigh the pros and cons, and always check the background and credentials of the physician and pharmacy providing the therapy